Nanoparticle‑based delivery systems for targeted therapy in brain tumors: Progress, challenges and perspectives (Review).

IF 4.9 3区 医学 Q1 ONCOLOGY
International journal of oncology Pub Date : 2025-10-01 Epub Date: 2025-08-24 DOI:10.3892/ijo.2025.5789
Jing-Xing Si, Zheng-Chuang Liu, Fang Gu, Xiaoli Jin, Ying-Yu Ma
{"title":"Nanoparticle‑based delivery systems for targeted therapy in brain tumors: Progress, challenges and perspectives (Review).","authors":"Jing-Xing Si, Zheng-Chuang Liu, Fang Gu, Xiaoli Jin, Ying-Yu Ma","doi":"10.3892/ijo.2025.5789","DOIUrl":null,"url":null,"abstract":"<p><p>Brain tumors, particularly gliomas, are among the most lethal malignancies, with high mortality driven by a delayed diagnosis and limited therapeutic efficacy. A central challenge lies in the presence of the blood‑brain barrier (BBB), which severely impedes the delivery of systemically administered therapeutics to tumor sites. Addressing this clinical urgency, nanoparticle (NP)‑based delivery systems have emerged as a transformative strategy to enhance brain‑specific drug accumulation, minimize off‑target toxicity and improve treatment outcomes. The present review systematically examined the recent advances in nanocarrier technologies for targeted brain tumor therapy, including liposomes, solid lipid NPs, dendrimers, polymeric nanoplatforms and inorganic nanomaterials. The design principles, mechanisms for BBB traversal, therapeutic payload compatibility and tumor‑targeting capabilities of NP technologies demonstrated in preclinical models have also been highlighted. In addition to drug delivery, emerging applications of nanocarriers in gene therapy were explored and the impact of protein corona formation on NP behavior <i>in vivo</i> was discussed. Finally, current translational bottlenecks were identified and future design considerations to achieve clinically viable, precision‑targeted nanomedicines for brain tumors were outlined.</p>","PeriodicalId":14175,"journal":{"name":"International journal of oncology","volume":"67 4","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12370360/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/ijo.2025.5789","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Brain tumors, particularly gliomas, are among the most lethal malignancies, with high mortality driven by a delayed diagnosis and limited therapeutic efficacy. A central challenge lies in the presence of the blood‑brain barrier (BBB), which severely impedes the delivery of systemically administered therapeutics to tumor sites. Addressing this clinical urgency, nanoparticle (NP)‑based delivery systems have emerged as a transformative strategy to enhance brain‑specific drug accumulation, minimize off‑target toxicity and improve treatment outcomes. The present review systematically examined the recent advances in nanocarrier technologies for targeted brain tumor therapy, including liposomes, solid lipid NPs, dendrimers, polymeric nanoplatforms and inorganic nanomaterials. The design principles, mechanisms for BBB traversal, therapeutic payload compatibility and tumor‑targeting capabilities of NP technologies demonstrated in preclinical models have also been highlighted. In addition to drug delivery, emerging applications of nanocarriers in gene therapy were explored and the impact of protein corona formation on NP behavior in vivo was discussed. Finally, current translational bottlenecks were identified and future design considerations to achieve clinically viable, precision‑targeted nanomedicines for brain tumors were outlined.

Abstract Image

Abstract Image

基于纳米颗粒的脑肿瘤靶向治疗递送系统:进展、挑战和前景(综述)。
脑肿瘤,特别是胶质瘤,是最致命的恶性肿瘤之一,由于诊断迟缓和治疗效果有限,死亡率很高。主要的挑战在于血脑屏障(BBB)的存在,这严重阻碍了系统给药治疗药物向肿瘤部位的输送。为了解决这一临床紧迫性,基于纳米颗粒(NP)的给药系统已经成为一种变革性的策略,可以增强大脑特异性药物积累,最大限度地减少脱靶毒性并改善治疗结果。本文系统地综述了靶向脑肿瘤治疗的纳米载体技术的最新进展,包括脂质体、固体脂质NPs、树状大分子、聚合物纳米平台和无机纳米材料。本文还强调了NP技术在临床前模型中展示的设计原则、血脑屏障穿越机制、治疗有效载荷兼容性和肿瘤靶向能力。除药物递送外,还探讨了纳米载体在基因治疗中的新应用,并讨论了蛋白质冠形成对体内NP行为的影响。最后,确定了当前的转化瓶颈,并概述了未来设计考虑因素,以实现临床可行的、精确靶向的脑肿瘤纳米药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.60
自引率
0.00%
发文量
157
审稿时长
2.1 months
期刊介绍: The main aim of Spandidos Publications is to facilitate scientific communication in a clear, concise and objective manner, while striving to provide prompt publication of original works of high quality. The journals largely concentrate on molecular and experimental medicine, oncology, clinical and experimental cancer treatment and biomedical research. All journals published by Spandidos Publications Ltd. maintain the highest standards of quality, and the members of their Editorial Boards are world-renowned scientists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信